Skip to main content

Fluidigm IPO Delayed Until Next Week

NEW YORK (GenomeWeb News) – Amid the volatility in the stock market, the anticipated initial public offering from Fluidigm, which was expected to become effective either Thursday or Friday this week, has been postponed until next week.
 
The South San Francisco, Calif.-based firm still expects to float at $14 to $16 per share and raise net proceeds of roughly $70.8 million, assuming an offering price of $15 per share. If the underwriters’ over-allotment option is exercised in full, Fluidigm could receive net proceeds of $81.9 million.
 
The firm initially filed for the IPO in April. Morgan Stanley is the book-running manager for the offering, with UBS, Leerink Swann, and Pacific Growth Equities acting as co-managers.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.